Présentation
Référence
7014
Statut
CE
Sample
30 µl de sang total citraté
Quantité
10 tests
Detection
Fluorescence
Application
Kits pour la Cytométrie de flux
Composition
- Diluant. - PGE1 - PGE1 +ADP - Fixateur - Anticorps monoclonal anti VASP-P - Contrôle isotypique négatif - Réactif de révélation-FITC + contre-marqueur plaquettaire (CD61-PE).
Principe
L'échantillon sanguin est incubé parallèlement en présence de PGE1 seule ou de PGE1+ ADP. Aprés une perméabilisation cellulaire, la molécule VASP sous forme phosphorylée est marquée en immunofluorescence indirecte sans lavage par un anticorps monoclonal spécifique. L'analyse en cytométrie en flux , en double couleur , permet de comparer les deux conditions testées et d'évaluer, pour l'échantillon analysé, la capacité de l'ADP à inhiber cette phosphorylation.
Téléchargement
Date | Nom du document | Téléchargement |
---|---|---|
01/03/2015 | Package insert PLT VASP P2Y12 |
DE (500.52 KB)
EN (175.26 KB) ES (543.38 KB) FR (243.07 KB) IT (526.13 KB) PT (530.45 KB) |
08/06/2010 | Flyer PLT VASP P2Y12 | EN (592.82 KB) |
Bibliographie
Auteur | Titre | Année d'édition | Revue |
---|---|---|---|
Resistance to thienopyridines : clinical detection of coronary stent thrombosis by monitoring of vasodilatator-stimulated phosphoprotein phosphorylation
|
2003
|
Cathet Cardiovasc Intervent
|
|
Flow cytometry analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases
|
2005
|
J Thromb Haemost
|
|
High stability of blood samples for flowcytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease
|
2005
|
Thromb Haemost.
|
|
Inter-individual variability in the response to clopidogrel
|
2005
|
Archives des Maladies du Coeur et des Vaisseaux
|
|
Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis, Results of the CREST Study
|
2005
|
J Am Coll Cardiol
|
|
A randomized comparison of high clopidogrel loading doses in patients with non -ST-Segment elevation Acute coronary syndromes
|
2006
|
JACC
|
|
Influence of omeprazol on the anti platelet action of clopidogrel associated to aspirin
|
2006
|
J Thromb Haemost
|
|
Role of the P2Y12 gene polymorphism in the platelet responsiveness to clopidogrel in healty subjects
|
2006
|
J Thromb Haemost
|
|
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
|
2006
|
Blood
|
|
Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation
|
2006
|
Transfusion
|
|
Comparison of VASP phosphorylation assay to light transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor
|
2006
|
Thromb Haemost.
|
|
Drug insight : clopidogrel responsiveness
|
2006
|
Nat Clin Pract Cardiovasc Med
|
|
Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases
|
2007
|
J Thromb Haemost
|
|
Randomized comparison of a high clopidogrel maintenance dose in patients with Diabetis mellitus and coronary artery disease
|
2007
|
Circulation
|
|
The flow cytometric VASP assay can be used to determined the effectiveness of clopidogrel in patients treated with Abciximab
|
2007
|
J Thromb Haemost
|
|
Lack of association between the 807C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome
|
2007
|
Thromb Haemost.
|
|
Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate® analyzer -comparison with two flow cytometric methods"
|
2007
|
Thromb Res
|
|
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome
|
2007
|
Thromb Res
|
|
VASP phosphorylation analysis prior to percutaneous coronary intervention for exclusion of post-procedural major adverse cardiovascular events
|
2007
|
J Thromb Haemost
|
|
Platelet P2 receptors: old and new targets for antithrombotic drugs
|
2007
|
Cardiovascular Therapy
|
|
Assessment of clopidogrel responsiveness : measurements of maximum platelet agreggation, final platelet agreggation and their correlation with Vasodilator stimulated phosphoprotein in resistant patients
|
2007
|
Thromb Res
|
|
Biomarker optimization to track antithrombotic and hemostatic effects of clopidogrel
|
2007
|
J Pharmacol Exp Ther.
|
|
Platelet function, antiplatelet therapy and clinicla outcomes : to test or not to test ?
|
2007
|
J Thromb Haemost
|
|
Different methodologies for evaluating the effect of clopidogrel on platelet function in high isk coronary artery disease patients
|
2007
|
J Thromb Haemost
|
|
The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin
|
2007
|
Thromb Haemost.
|
|
Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopicogrel responsiveness
|
2007
|
Thromb Haemost.
|
|
Impaired platelet responsiveness to clopidogrel identified by flow cytometric VASP phosphorylation in patients with subacute stent thrombosis
|
2007
|
Thromb Haemost.
|
|
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome
|
2007
|
Thromb Haemost.
|
|
Platelet function monitoring in patients with coronary artery disease
|
2007
|
JACC
|
|
The Significance of Vasodilator-Stimulated Phosphoprotein for Risk Stratification of Stent Thrombosis
|
2007
|
Thromb Haemost.
|
|
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease
|
2007
|
Am Heart J
|
|
Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: Shall we routinely test platelet function ?
|
2007
|
Thromb Haemost.
|
|
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|
2007
|
Circulation
|
|
Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
|
2008
|
European Heart Journal
|
|
Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation
|
2008
|
Cytometry Part B
|
|
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study
|
2008
|
J. Am. Coll. Cardiol.
|
|
Omeprazole A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel
|
2008
|
J. Am. Coll. Cardiol.
|
|
Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome
|
2008
|
Am J Cardiol.
|
|
Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition onStandard Dose Treatment
|
2008
|
Am J Cardiol.
|
|
Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicentre Randomized Prospective Study
|
2008
|
J. Am. Coll. Cardiol.
|
|
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
|
2008
|
Thromb Haemost.
|
|
Determinants of thrombin generation,fibrinolytic activity, and endothelial dysfunctionin dual-antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow’s triad
|
2008
|
Eur Heart J.
|
|
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects
|
2008
|
J Thromb Haemost
|
|
A threshold of platelet reactivity for ischaemic events?
|
2008
|
Eur Heart J.
|
|
Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention
|
2008
|
Thromb Res
|
|
P2Y12 Antagonism: Promises and Challenges
|
2008
|
ATVB
|
|
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
|
2008
|
Eur Heart J.
|
|
ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay
|
2008
|
Thromb Haemost
|
|
Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
|
2008
|
J. Am. Coll. Cardiol.
|
|
Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
|
2008
|
Thromb Haemost
|
|
Thienopyridine Resistance Among Patients Undergoing Intracoronary Stent Implantation and Treated With Dual Antiplatelet Therapy: Assessment of Some Modifying Factors
|
2008
|
J Pharmacol Sci
|
|
Clinical implications of clopidogrel resistance
|
2008
|
Thromb Haemost.
|
|
Methods to Evaluate the Pharmacology of Oral Antiplatelet Drugs
|
2008
|
Herz
|
|
Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention"
|
2008
|
J Am Coll Cardiol Intv
|
|
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
|
2008
|
J. Am. Coll. Cardiol.
|
|
Flow cytometric assessment of vasodilator-stimulated phosphoprotein: Prognostic value of recurrent cardiovascular events after acute coronary syndromes
|
2008
|
Arch Cardiovasc Dis.
|
|
Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis
|
2009
|
Am J Cardiol.
|
|
Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits
|
2009
|
Thromb Res
|
|
The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
|
2009
|
Thromb Res
|
|
Emergence of the Concept of Platelet Reactivity Monitoring of Response to Thienopyridines
|
2009
|
Heart
|
|
Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment
|
2009
|
Thrombosis Journal
|
|
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response
|
2009
|
Thromb Res.
|
|
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
|
2009
|
Eur Heart J
|
|
High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial
|
2009
|
Blood Coagul Fibrinolysis
|
|
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
|
2009
|
European Heart Journal
|
|
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non ST-elevation acute coronay syndrome
|
2009
|
EuroIntervention
|
|
CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring
|
2009
|
J Thromb Haemost
|
|
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
|
2009
|
Am Heart J
|
|
Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose
|
2009
|
J. Am. Coll. Cardiol.
|
|
Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery
|
2009
|
Thromb Res
|
|
Cross validation of the Multiple Electrode Aggregometry
|
2009
|
Thromb Haemost.
|
|
Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation
|
2009
|
Thromb Haemost.
|
|
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
|
2009
|
Am Heart J
|
|
Selecting Optimal Antiplatelet Therapy Based on Platelet Function Monitoring in Patients With Coronary Artery Disease
|
2009
|
Curr Treat Op Cardio Med
|
|
CYP2C19*17 Allele is associated with Better Platelet Response to Clopidogrel in patients admitted for Non-ST Acute Coronary Syndrome
|
2009
|
J Thromb Haemost.
|
|
Clopidogrel resistance Live" - the risk of stent thrombosis should be evaluated before procedures
|
2009
|
Thrombosis J
|
|
Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness
|
2010
|
Int J Cardiol.
|
|
A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study
|
2010
|
Thromb Res
|
|
Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism
|
2010
|
Int J cardiol.
|
|
Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients
|
2010
|
Thromb Res.
|
|
Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry
|
2010
|
Blood Coagulation and Fibrinolysis
|
|
The Effect of Elinogrel on High Platelet Reactivity During Dual Antiplatelet Therapy and the Relation to CYP 2C19*2 Genotype:First Experience in Patients
|
2010
|
J Thromb Haemost.
|
|
Slow Response to Clopidogrel Predicts Low Response
|
2010
|
J. Am. Coll. Cardiol.
|
|
Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring
|
2010
|
Eur J Anaesthesiol.
|
|
Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting
|
2010
|
Archives of Cardiovascular Disease
|
|
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. The RESPOND Study
|
2010
|
Circulation
|
|
Pharmacodynamics and Pharmacokinetics of Single Doses of Prasugrel 30 mg and Clopidogrel 300 mg in Healthy Chinese and White Volunteers: An Open-Label Trial
|
2010
|
Clin Ther.
|
|
The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats
|
2010
|
Thromb Res
|
|
Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel
|
2010
|
J Thromb Haemost.
|
|
Effects of Polyunsaturated Omega-3 Fatty Acids on Responsiveness to Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
|
2010
|
J. Am. Coll. Cardiol.
|
|
Impact of P2Y12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty
|
2010
|
J Am Coll Cardiol Intv
|
|
Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19 2* Loss of Function Polymorphism
|
2010
|
J. Am. Coll. Cardiol.
|
|
Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?
|
2010
|
J Thromb Haemost.Â
|
|
Comparison of conventional aggregomerty with VASP for monitoring P2Y12-specifc platelet inhibition
|
2010
|
Platelets
|
|
Usefulness of a flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of patients with genetic defects of the platelet P2y12 receptor for ADP
|
2010
|
J Thromb Haemost.Â
|
|
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
|
2010
|
J. Am Coll Cardiol.
|
|
Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy
|
2010
|
J. Am. Coll. Cardiol.
|
|
Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (SWitching Anti Platelet) Study
|
2010
|
J. Am. Coll. Cardiol.
|
|
Level of P2Y12-ADP receptor blockade during percutaneous coronary intervention predicts the extent of endothelial injury,assessed by CEC measurement
|
2010
|
J. Am. Coll. Cardiol.
|
|
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest
|
2010
|
Resuscitation
|
|
Comparison of platelet P2Y12 ADP receptor mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP phosphorylation in japanese patients undergoing coronary stenting
|
2010
|
Int Heart J.
|
|
Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study
|
2010
|
J Thromb Haemost.
|
|
Pharmacodynamic effects of concomitant versus stagerred clopidogrel and omeprazole intake
|
2010
|
Circ Cardiovasc Interv.
|
|
First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel. The ONSET/OFFSET and RESPOND Genotype Studies
|
2010
|
Circ Cardiovasc Genet.
|
|
A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction"
|
2010
|
Catheter Cardiovasc Interv.
|
|
Clopidogrel differentially affects platelet-mediated thrombosis and inflammatoryresponse in patients with acute coronary syndromes
|
2011
|
J Thromb Haemost.
|
|
Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors
|
2011
|
JPET
|
|
Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel
|
2011
|
J. Am. Coll. Cardiol.
|
|
Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease
|
2011
|
Thromb Haemost
|
|
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy
|
2011
|
Thromb Haemost
|
|
Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for predictionof postprocedural major adverse cardiovascular events
|
2011
|
Thromb Haemost
|
|
Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin's Advantage and the Smoking
|
2009
|
J Cardiovasc Pharmacol
|
|
Platelet function testing in hirudin and BAPA anticoagulated blood
|
2011
|
Clin Chem Lab Med
|
|
High on-clopidogrel platelet reactivity: Genotyping can help to optimize antiplatelet treatment
|
2011
|
Thromb Res
|
|
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
|
2011
|
Thrombosis Journal
|
|
Low platelet reactivity is recoverd by transfusion of stored platelets: A healthy volunteer in vivo study
|
2011
|
J Thromb Haemost
|
|
Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance
|
2011
|
Clin. Cardiol.
|
|
Clopidogrel pharmacokinetics and pharmacodynamics vary widely, independent of CYP2C19 polymorphisms, diet, smoking, proton pump inhibitors and other co-medications
|
2011
|
J. Am. Coll. Cardiol.
|
|
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy
|
2011
|
Thromb Haemost.
|
|
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses
|
2011
|
J Thromb Haemost
|
|
Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study
|
2011
|
J Thromb Haemost
|
|
Randomised Double Blind Placebo Controlled Crossover Study to Determine the Effects of Esomeprazole on Inhibition of Platelet Function by Clopidogrel
|
2011
|
J Thromb Haemost
|
|
High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes
|
2011
|
J. Am. Coll. Cardiol.
|
|
Pharmacodynamic evalutation of pentaprazole therapy on cloppidogrel effect
|
2011
|
Circ Cardiovasc Interv.
|
|
Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus
|
2011
|
Rev Esp Cardiol.
|
|
Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
|
2011
|
J Am Coll Cardiol Intv
|
|
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies
|
2011
|
Am Heart J.
|
|
PCI and clopidogrel: antiplatelet responsiveness and patient characteristics
|
2011
|
Acta Cardiol.
|
|
Relation of Body Mass Index to On-Treatment (Clopidogrel + Aspirin) Platelet Reactivity
|
2011
|
Am J Cardiol.
|
|
Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
|
2011
|
JAMA
|
|
Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome: Comparison With Clopidogrel Hydrogen Sulfate
|
2011
|
Angiology
|
|
Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance
|
2012
|
Eur J Int Med
|
|
The thrombin inhibitors, hirudin und Refludan®, activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets
|
2012
|
Thromb Haemost.
|
|
High on-treatment platelet reactivity assessed by various platelet function tests: Is the consensus-defined cutoff of VASP-P platelet reactivity index too low?"
|
2012
|
J Thromb Haemost
|
|
A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers
|
2012
|
J. Am. Coll. Cardiol.
|
|
Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis
|
2012
|
J Thromb Haemost
|
|
Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy
|
2012
|
J. Am. Coll. Cardiol.
|
|
Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus
|
2012
|
Rev Esp Cardiol.
|
|
Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity
|
2012
|
Eur J Clin Invest.
|
|
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention
|
2012
|
Thromb Res
|
|
Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel
|
2012
|
J Thromb Haemost
|
|
Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin
|
2012
|
J Thromb Thrombolysis
|
|
Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction
|
2012
|
Thromb Haemost.
|
|
Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade
|
2012
|
Thromb Res
|
|
Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients
|
2012
|
J Am Coll Cardiol
|
|
Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patientswith type 2 diabetes mellitus
|
2012
|
Thromb Haemost
|
|
CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome
|
2012
|
J Am Coll Cardiol Intv
|
|
Modified Diadenosine Tetraphosphates with Dual Specificity for P2Y1 and P2Y12 are Potent Antagonists of ADP-induced Platelet Activation
|
2012
|
J Thromb Haemost
|
|
Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus
|
2012
|
J Thromb Thrombolysis
|
|
The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.
|
2012
|
Thromb Haemost.
|
|
Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications
|
2013
|
Am J Cardiol.
|
|
Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation
|
2013
|
Transl Res.
|
|
Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-medications (Including Proton Pump Inhibitors), and Pre-existent Variability in Platelet F
|
2013
|
J Am Coll Cardiol
|
|
Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity
|
2013
|
Cardiovasc Revasc Med.
|
|
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
|
2013
|
J Hematol Oncol.
|
|
Investigation of drug–drug interactions between clopidogrel and fluoxetine
|
2013
|
Fundam. Clin. Pharmacol.
|
|
Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel
|
2013
|
J Am Coll Cardiol Intv
|
|
Impact of Prasugrel Reload Dosing Regimens on High On-Treatment Platelet Reactivity Rates in Patients on Maintenance Prasugrel Therapy
|
2013
|
J Am Coll Cardiol
|
|
Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral arterial disease
|
2013
|
Platelets
|
|
Relationship Between CYP2C19 Loss-of-Function Polymorphism and Platelet Reactivities With Clopidogrel Treatment in Japanese Patients Undergoing Coronary Stent Implantation
|
2013
|
Circ. J
|
|
Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin
|
2012
|
Circ J.
|
|
Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains noninferiority
|
2013
|
J Am Coll Cardiol
|
|
Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention
|
2013
|
Thromb Res.
|
|
Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in
|
2013
|
Am Heart J
|
|
CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Anti-Platelet Action of Clopidogrel
|
2013
|
J Cardiovasc Pharmacol.
|
|
Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping
|
2013
|
J Am Heart Assoc.
|
|
The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study
|
2013
|
J Am Coll Cardiol.
|
|
Response to antiplatelet therapy is independent of endogenous thrombin generation potential
|
2013
|
Thromb Res.
|
|
Impact of aspirin dose on adenosine diphosphate-mediated platelet activity Results of an in vitro pilot investigation
|
2013
|
Thromb Haemost
|
|
A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity
|
2013
|
Int J Cardiol.
|
|
Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine
|
2013
|
J Am Coll Cardiol
|
|
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching
|
2013
|
Thromb Haemost
|
|
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding
|
2013
|
J Am Coll Cardiol.
|
|
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention
|
2014
|
Eur Heart J.
|
|
Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome
|
2014
|
Thromb Haemost
|
|
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery
|
2014
|
Thromb Haemost
|
|
A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in PAR-1 in a patient with chronic bleeding
|
2014
|
J Thromb Haemost
|
|
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis
|
2014
|
Am J Emerg Med
|
|
Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and
|
2014
|
J Thromb Haemost
|
|
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.
|
2014
|
J Interv Cardiol.
|
|
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study.
|
2014
|
Thromb Res.
|
|
Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy
|
2014
|
Thromb Res.
|
|
The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese
|
2015
|
Scand J Clin Lab Invest
|
|
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?
|
2015
|
Thromb Haemost
|
|
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention
|
2015
|
Eur Heart J
|
|
Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry
|
2015
|
J Thromb Haemost
|
|
How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?
|
2016
|
Platelets
|
|
Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective study
|
2015
|
Int J Cardiol
|
|
Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry
|
2016
|
J Thromb Haemost.
|
|
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
|
2016
|
J Am Coll Cardiol
|
|
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors
|
2016
|
Thromb Haemost
|
|
Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects
|
2016
|
Drug Metab Pharmacokinet
|
|
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study
|
2016
|
Circulation
|
|
Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects
|
2016
|
Drug Metab Pharmacokinet
|
|
The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration.
|
2021
|
Platelets
|
Produits associés
Titre | Référence |
---|---|
CY-QUANT VASP/P2Y12 |
7502
|